Kunming Biomed (KBI)
An International Leading CRO Providing High-Quality Services for New Drug Discovery and Development with NHP Disease Models
Kunming Biomed International Ltd. (KBI) conducts studies including PK/PD, pathology and exploratory toxicology with non-human primate (NHP) disease models for metabolic, nervous, cardiovascular, hepatic, renal, ophthalmic diseases, immune inflammation, etc. KBI owns AAALAC-accredited vivarium, state-of-the-art research facilities, excellent pathology laboratories, clinical sample analysis laboratories, biomarker laboratories, etc. We uphold the highest ethical standards for animal care and welfare, and provide R&D services for domestic and global pharmaceutical and biotechnology companies and academic institutions worldwide.